CRSP250117C110000
- 0.01
- 0.000.00%
CRISPR Therapeutics Newsroom
Needham Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $84
Buy Rating for Crispr Therapeutics AG: Strong Pipeline, Strategic Partnerships, and Financial Stability Drive Confidence
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Gene Editing Stocks Drop as Intellia Announces Layoffs
OptionMetrics and CRSP Announce Partnership Giving Academic Researchers Increased Integration of U.S. Equities and Options Data in Research
CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
Press Release: CRISPR Therapeutics Proposes New Appointment to the Board of Directors
BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $85
Cathie Wood's ARK Innovation ETF Couldn't Keep Up in 2024
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
CRISPR Therapeutics AG's (NASDAQ:CRSP) Recent 4.5% Pullback Adds to One-year Year Losses, Institutional Owners May Take Drastic Measures
CRISPR Therapeutics AG (CRSP): Is This Gene Therapy Stock a Good Buy Right Now?
Institutional Investors May Adopt Severe Steps After CRISPR Therapeutics AG's (NASDAQ:CRSP) Latest 8.3% Drop Adds to a Year Losses
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
JMP Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $86
CRISPR Therapeutics: Promising Developments and Positive Outlook Amid Advancements in Gene-Editing
1 Big New Green Flag for CRISPR Therapeutics' Stock
Clear Street Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating, Announces Target Price $45